AOC Spent $19K In Campaign Funds On Ketamine Psychiatrist (This is Not A Bad Thing!)
Federal Election Commission filings reveal that Rep. Alexandria Ocasio Cortez’s campaign paid nearly $19,000 to a psychiatrist who specializes in ketamine assisted therapy. The payments went to Dr. Bryan Boyle, chief psychiatric officer at Stella, a mental health clinic chain known for innovative treatment protocols. Campaign records list the expenses as “leadership training and consulting.” The story has generated national media attention and reignited a broader conversation about ketamine therapy and its growing role in mainstream mental health care.
| Key Takeaway | Details |
|---|---|
| Total Spent | $18,725 across three payments in 2025 |
| Psychiatrist | Dr. Bryan Boyle, Harvard trained, chief psychiatric officer at Stella |
| Listed Purpose | “Leadership training and consulting” |
| Legal Question | FEC rules prohibit personal expenses from campaign funds |
| Broader Context | AOC has proposed psychedelic research legislation three times |
What This Means for Ketamine Therapy
The political debate aside, this story highlights something important. Ketamine therapy continues to move from the margins of mental health care into wider public awareness. Stella, the clinic where Dr. Boyle practices, offers treatments for PTSD, depression and anxiety using protocols that include ketamine assisted therapy. These are real clinical services backed by a growing body of research.
Every time ketamine appears in a headline, it creates an opportunity. More people learn that FDA approved ketamine treatments exist. More people discover that this is not fringe medicine. It is an evidence based approach that has changed lives for patients who found no relief through traditional options.
The Bigger Picture
Ocasio Cortez has introduced legislation three times to expand psychedelic research for mental illness treatment. Regardless of where anyone stands politically, that track record signals a shift. Elected officials are engaging with psychedelic medicine as a serious policy matter.
For patients exploring ketamine therapy, the clinical facts remain clear. Ketamine has decades of medical use. The FDA approved esketamine nasal spray for treatment resistant depression in 2019. Clinics across the country now offer supervised ketamine treatments under medical guidance.
The headlines will fade. The science will not. If you or someone you know is considering ketamine therapy, the most important step is connecting with a qualified provider who can evaluate whether this treatment fits your needs.
